Interim report
Page 1
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ----------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------ Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com October 27, 2026 To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO To General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960 Sub.: Outcome of Board Meeting held today i.e. Tuesday, October 27, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time. Dear Sir/ Ma’am, With reference to the intimation of Board meeting submitted on October 22, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the following: 1. UN-AUDITED FINANCIAL RESULTS On review and recommendation of Audit Committee of the Company , has inter-alia considered and approved, the unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the unaudited Standalone and Consolidated Financial Results of the Company for the second quarter and half year ended on September 30, 2026, along with the Limited Review Reports issued by M/s. BSR & Co. LLP, the Statutory Auditors. 2. RECORD DATE FOR ISSUE OF BONUS EQUITY SHARES With reference to the intimation of outcome of Board meeting dated September 23, 2026, the Board has fixed Wednesday, November 04, 2026 as record date for the purpose of identifying the shareholders to whom Bonus Equity shares shall be allotted. The Company shall also make a separate disclosure in this regard to the Stock Exchange. 3. RECONSTITUTION OF COMMITTEES OF BOARD Pursuant to Regulation 30 read with Regulations 18, 19, & 21 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has reconstituted the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee and Corporate Social Responsibility Committee of the Company. The revised composition of the aforesaid Committees is enclosed herewith as Annexure A. The Board Meeting commenced at 03:30 P.M. and concluded at 04:45 P.M. This is for your information and records. For Concord Biotech Limited Paritosh Trivedi Company Secretary and Compliance Officer ACS 63623
Page 2
B S R & Co. LLP Chartered Accountants 903 Commerce House V Near Vodafone House, Prahaladnagar Corporate Road, Ahmedabad 380 051 India Telephone: +91 (79) 7145 0001 Fax: +91 (79) 7145 0050 Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 3 Limited Review Report on unaudited consolidated financial results of Concord Biotech Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Concord Biotech Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Concord Biotech Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the entities mentioned in Annexure I to the Statement. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Page 3
B S R & Co. LLP Limited Review Report (Continued) Concord Biotech Limited Page 2 of 3 6. We did not review the interim financial information of two Subsidiaries included in the Statement, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 316.71 lakhs as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 52.72 lakhs and Rs. 79.58 lakhs, total net profit/(loss) after tax (before consolidation adjustments) of Rs. 0.22 lakhs and Rs. (7.47) lakhs and total comprehensive profit/(loss) (before consolidation adjustments) of Rs. 0.22 lakhs and Rs. (7.47) lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash inflows (net) (before consolidation adjustments) of Rs. 6.55 lakhs for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Parent’s management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion is not modified in respect of this matter. 7. The Statement includes the interim financial information of one Subsidiary which has not been reviewed, whose interim financial information reflects total assets (before consolidation adjustments) of Rs. 1,360.51 lakhs as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 65.65 lakhs and Rs. 73.24 lakhs, total net (loss) after tax (before consolidation adjustments) of Rs. (432.63) lakhs and Rs. (764.36) lakhs and total comprehensive loss (before consolidation adjustments) of Rs. (450.82) lakhs and Rs (781.68) lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. (279.75) lakhs for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. The Statement also includes the Group’s share of net profit after tax (before consolidation adjustments) of Rs. 29.06 lakhs and Rs. 35.32 lakhs and total comprehensive income (before consolidation adjustments) of Rs. 29.06 lakhs and Rs. 35.32 lakhs, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively as considered in the Statement, in respect of one joint venture, based on its interim financial information which has not been reviewed. According to the information and explanations given to us by the Parent’s management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of this matter. For B S R & Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 Rupen Shah Partner Mumbai Membership No.: 116240 27 October 2026 UDIN:26116240WJNZHC6030
Page 4
B S R & Co. LLP Limited Review Report (Continued) Concord Biotech Limited Page 3 of 3 Annexure I List of entities included in unaudited consolidated financial results. Sr. No Name of component Relationship 1 Concord Biotech Limited Parent Company 2 Concord Lifegen Limited Wholly owned subsidiary 3 Celliimune Biotech Private Limited Wholly owned subsidiary 4 Stellon Biotech Inc. Subsidiary 5 Concord Biotech Japan K.K. Joint Venture
Page 5
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com Sr. No. STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026 Particulars (Rs. In lakhs except per share data) Quarter Ended Six Month Ended Year Ended 30-Sep-26 (Unaudited) 30-Jun-26 (Unaudited) 30-Sep-25 (Unaudited) 30-Sep-26 (Unaudited) 30-Sep-25 (Unaudited) 31-Mar-26 (Audited) 1 Income Revenue from operations Other income Total Income 30,907.02 25,748.90 24,705.75 56,655.92 1,016.93 1,282.59 31,923.95 27,031.49 1,335.21 26,040.96 2,299.52 45,104.51 2,702.97 1,05,489.07 5,235.53 58,955.44 47,807.48 1,10,724.60 Expenses Cost of materials consumed Purchase of stock-in-trade 6,366.30 1,624.47 Changes in inventories of finished goods, work-in-progress and (634.88) 6,985.45 1,129.00 (2,685.35) 5,730.43 1,364.51 (2,193.31) 13,351.75 2,753.47 (3,320.22) 11,721.41 2,649.14 (4,958.41) 25,434.78 6,260.63 (7,128.30) stock-in-trade Employee benefits expense 5,231.43 4,363.81 4,445.55 9,595.25 8,235.29 17,690.48 Finance costs 3.34 3.64 5.91 6.98 11.77 28.32 Depreciation and amortisation expense 1,837.68 1,809.95 1,839.15 3,647.63 3,616.78 7,445.86 Other expenses Power and fuel 3,663.78 3,472.01 2,852.80 7,135.79 5,800.30 11,619.93 Others 4,217.91 4.246.40 3,656.66 8,464.31 6,667.98 14,871.56 Total Expenses 22,310.03 19,324.91 17,701.70 41,634.96 33,744.26 76.223.26 3 Profit before exceptional items and tax (1-2) 9,613.92 7,706.58 8,339.26 17,320.48 14,063.22 34,501.34 Exceptional items: Statutory impact of new labour codes (refer note 2) 327.54 5 Profit before tax and share of profit of joint venture (3-4) 9,613.92 7,706.58 8,339.26 17,320.48 14,063.22 34,173.80 Share of profit of joint venture (net of tax) (65.88) 127.73 229.14 61.85 378.37 290.92 7 Profit before tax (5+6) 9,548.04 7,834.31 8,568.40 17,382.33 14,441.59 34,464.72 Tax expenses: a Current tax b Deferred tax Total tax expenses Profit after tax for the period/year (7-8) 2,498.30 92.54 2,036.59 28.03 2,199.60 4,534.89 3,607.45 120.57 122.07 8,629.09 (87.28) 2,590.84 2,064.62 2,262.12 4,655.46 3,729.52 8,541.81 6,957.20 5,769.69 6,306.28 12,726.87 10,712.07 25,922.91 10 Other comprehensive income (net of tax) Items that will not be reclassified to profit or loss Re-measurement gain/ (loss) on defined benefit plans b Income tax relating to re-measurement gain/ (loss) on defined benefit plans (103.90) 26.15 71.56 (18.01) 2.02 (0.51) (32.34) 8.14 (30.05) 7.56 (162.24) 40.83 Fair value changes on equity investments through OCI Income tax relating to fair value changes on equity investments (892.10) 1,927.33 127.57 (275.61) 2,598.15 (408.99) 1,035.23 (148.04) 2,253.54 (322.26) 6,687.09 (987.87) through OСІ Items that will be reclassified to profit or loss Foreign currency translation reserves (18.18) 0.87 (5.49) (17.31) (5.49) (53.45) Other comprehensive income for the period/year (860.46) 1,706.14 2,185.18 845.68 1,903.30 5,524.36 11 Total comprehensive income for the period/year(9+10) 6,096.74 7,475.83 8,491.46 13.572.55 12.615.37 31.447.27 12 Profit for the period attributable to: Owners of the company Non-controlling interest Profit for the period 7,065.35 5,852.62 6,358.09 (108.15) (82.931 (51.81) 12,917.96 (191.09) 10,763.88 6,957.20 5,769.69 6,306.28 12,726.87 (51.81) 10,712.07 26,090.59 (167.68) 25,922.91 13 Other comprehensive income for the period attributable to: Owners of the company (855.93) 1,705.93 Non-controlling interest (4.53) 0.21 2,186.55 (1.37) 850.00 (4.32) 1,904.67 (1.37) 5,537.72 (13.36) Other comprehensive income for the period (860.46) 1,706.14 2,185.18 845.68 1,903.30 5,524.36 14 Total comprehensive income for the period attributable to: Owners of the company 6,209.42 Non-controlling interest (112.68) 7,558.55 (82.72) 8,544.65 (53.18) 13,767.96 (195.41 Total comprehensive income for the period 6,096.74 7,475.83 8,491.46 13,572.55 12,668.55 (53.18) 12,615.37 31,628.31 (181.04) 31,447.27 15 Paid-up equity share capital (face value of Rs. 1/- each) 1,046.16 1,046.16 1,046.16 1,046.16 1,046.16 16 lothOther equity 1,046.16 2,00,659.97 17 Earnings per share Basic and diluted (In Rs.) (not annualised for the quarter) 6.65 5.52 6.03 12.17 10.24 24.78 Refer notes to the unaudited consolidated financial results Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 6
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com Notes to the statement of unaudited consolidated financial results for the quarter and six months ended September 30, 2026: 1. The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on October 27, 2026. The Statutory Auditors of the holding company have carried out a limited review of the said results. 2. On November 21, 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment notified Central Rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Group has recognized an incremental liability of 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31, 2026. The Group continues to monitor further clarifications/FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 3. The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment". 4. The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI"). 5. Celliimune Biotech Private Limited that was incorporated on January 15, 2025 has been acquired by Concord Biotech Limited as on April 02, 2026. Accordingly, Celliimune Biotech Private Limited is a wholly owned subsidiary from April 02, 2026. 6. The holding company has increased the Authorised Share Capital from 1,100 lacs, divided into 11,00,00,000 (Eleven Crores) Equity Shares of ₹ 1/- (Rupees One only) each, to ₹ 2,200 lacs, divided into 22,00,00,000 (Twenty-two crores) Equity Shares of 1/- (Rupees One only) each, by creation of an additional 11,00,00,000 (Eleven Crores) Equity Shares of 1/- (Rupees One only) each, ranking pari passu in all respects with the existing Equity Shares of the holding company and consequential amendment to Capital Clause of the Memorandum of Association of the holding company, subject to approval of the Shareholders. The holding company has also declared Bonus shares in the proportion of 1:1 i.e. 1 (One) Bonus equity share of ₹ 1/- each for every 1 (One) fully paid-up equity share of ₹ 1/- each held by the Shareholders of the holding company in the Board meeting held on September 23, 2026. For and on behalf of board of directors of Concord Biotech Limited Place: Ahmedabad Date: October 27, 2026 Sudhir Vaid Chairman & Managing Director DIN: 00055967 ☐ Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 7
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com CONSOLIDATED UNAUDITED STATEMENT OF ASSETS & LIABILITIES Particulars (in Lakhs) As at 30 Sep 2026 (Unaudited) As at 31 March 2026 (Audited) Assets I. Non-current assets (a) Property, plant and equipment (b) Capital work-in-progress (c) Intangible assets (d) Right-of use assets (e) Goodwill 75,964.07 78,571.73 11,164.94 7,815.92 309.12 25.97 163.40 218.07 45.10 39.63 (f) Intangible assets under development 209.46 116.51 (g) Investment accounted for using the equity method (h) Financial assets (i) Investments (ii) Other Financial Assets (i) Other non-current assets (j) Income tax assets (net) (k) Deferred tax assets (net) II. Current assets (a) Inventories (b) Financial assets Total non-current assets (A) 426.41 364.57 9,531.29 8,493.72 1,939.20 646.42 2,482.93 1,591.52 1,027.94 283.81 365.44 293.66 1,03,629.30 98,461.53 39.778.65 32.635.61 (i) Investments 43,810.01 40,206.37 (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Other Financial Assets (c) Other Current assets 41.249.08 46,019.71 752.27 1,218.60 13.19 139.30 1,378.24 2,524.01 2,086.05 2,267.59 Total current assets (B) 1,29,067.49 1,25,011.18 TOTAL ASSETS (A) + (B) 2,32,696.79 2,23,472.71 EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity (c) Non controlling Interest LIABILITIES I. Non-current liabilities (a) Financial liabilities (i) Lease liabilities (b) Provisions (c) Deferred tax liabilities (net) II. Current liabilities (a) Financial liabilities 1,046.16 1,046.16 2,06,529.36 2,00,659.97 2,07,575.52 2,01,706.13 (387.75) (192.33) Total equity (A) 2,07,187.77 2,01,513.80 Equity attributable to owners of the company 146.51 143.34 327.74 371.97 4,864.04 4,535.89 Total non-current liabilities (B) 5,338.29 5.051.20 (i) Lease liabilities 28.45 88.22 (ii) Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises 1,472.98 1,474.95 9,740.33 8,715.99 (iii) Other Financial Liabilities 4,803.07 4,270.41 (b) Provisions 1,243.82 1,123.43 (c) Other current liabilities 2,860.23 1,233.79 (d) Current tax liabilities (net) 21.85 0.92 Total current liabilities (C) 20,170.73 16,907.71 Total Liabilities (D) 25,509.02 21,958.91 TOTAL EQUITY AND LIABILITIES (A) + (D) 2,32,696.79 2,23,472.71 Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 8
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com Particulars UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW For the Six month ended 30 Sep 2026 (Unaudited) ( in Lakhs) For the Six month ended 30 Sep 2025 (Unaudited) (A) CASH FLOW FROM OPERATING ACTIVITIES Profit before tax as per Statement of Profit and Loss Adjustment for: Share of loss/(profit) from joint venture Depreciation and amortization expenses Provision for sales return Interest Income Finance Cost 17,382.33 14,441.59 (61.85) (378.37) 3,647.63 3,616.78 105.26 50.69 (62.19) (132.22) 6.98 11.77 Net gain/loss on termination of lease (4.47) (Reversal) /Provision for loss allowance 108.09 97.33 Excess provision no longer required written back (17.89) (179.84) (Profit)/loss on sale/discard of Property, plant & equipment (29.28) (1.30) Net gain on sale of investments (301.85) (989.75) Net gain on financial assets measured at fair value through profit or loss (1,021.44) (238.01 Net unrealised foreign exchange (gain) /loss (277.33) (690.11) Operating Profit before Working Capital Changes 19,473.99 15,608.56 Working Capital Changes: (Increase) in Inventories Decrease in trade receivables Decrease/(Increase) in other financial assets Decrease/(Increase) in other assets (Decrease) in provisions Increase/(Decrease) in trade payables Increase in other financial liabilities Increase in other liabilities Cash generated from operations Direct Taxes paid (Net of Income Tax refund) Net cash generated from operating activities (7,143.04) (3,661.01) 4,912.22 13,079.04 1,127.65 (967.66) 192.23 (997.42) (61.45) (113.98) 1,145.44 (2,522.03) 877.44 197.66 1,626.44 673.74 2.676.93 5,688.34 22,150.92 21,296.90 (5,329.87) (6,188.43) 16,821.05 15,108.47 (B) CASH FLOW FROM INVESTING ACTIVITIES Purchase of Property, plant & equipment and Intangible Assets (including CWIP and (5,998.57) (5,349.93) capital advance) Proceeds from disposal of Property, plant & equipment 36.08 10.65 Purchase of Current Investments (42,262.34) (46,133.26) Proceeds from sale of Current Investment 39,979.65 47,780.47 Interest received 62.19 132.22 Proceeds from Bank Deposits (Net) (including margin money deposits) 1,431.40 Investment in Current deposits with banks (including margin money deposits) 126.11 Proceeds from Non current deposits with Bank (including margin money deposits) (1,274.66) Net cash used in investing activities (9,331.54) (2,128.45) (C) CASH FLOW FROM FINANCING ACTIVITIES Repayment of current borrowings Dividend Paid (net of TDS) Interest Paid Principal Payment of Lease Liabilities Interest paid on Lease Liabilities Net cash used in financing activities NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C) CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR CASH AND CASH EQUIVALENTS AT END OF THE YEAR Cash and cash equivalents comprises of: Cash on hand Balance with Banks Total (38.11) (7,898.40) (11,193.67) 5.22 (56.60) (98.16) (6.06) (11.72) (7,955.84) (11,341.66) (466.33) 1,638.36 1,218.60 90.45 752.27 1,728.81 As at 30 Sep 2026 As at 30 Sep 2025 1.99 2.67 750.28 752.27 1,726.14 1,728.81 Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 9
B S R & Co. LLP Chartered Accountants 903 Commerce House V Near Vodafone House, Prahaladnagar Corporate Road, Ahmedabad 380 051 India Telephone: +91 (79) 7145 0001 Fax: +91 (79) 7145 0050 Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 1 Limited Review Report on unaudited standalone financial results of Concord Biotech Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of Concord Biotech Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of Concord Biotech Limited (hereinafter referred to as “the Company”) for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 (“the Statement”). 2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For B S R & Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 Mumbai 27 October 2026 Rupen Shah Partner Membership No.: 116240 UDIN:26116240TRCVOZ9213
Page 10
Sr. No. CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026 Particulars (Rs. In lakhs except per share data) Quarter Ended Six Month Ended Year Ended 30-Sept-26 30-Jun-26 30-Sept-25 30-Sep-26 30-Sep-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income a Revenue from operations b Other income Total Income 31,231.38 1,045.43 26,051.71 1,309.64 24,705.75 1,342.91 57,283.09 45,104.51 2,355.07 1,05,507.10 5,273.06 32,276.81 27,361.35 26,048.66 59,638.16 47,815.18 1,10,780.16 2,710.67 2 Expenses a Cost of materials consumed 6,366.30 6,985.45 5,730.43 13,351.75 11,721.41 25,434.78 b Purchase of stock-in-trade 1,569.52 1,125.96 1,364.51 2,695.48 2,649.14 6,222.86 C Changes in inventories of finished goods, work-in-progress and (365.56) (2,547.18) (2,193.31) (2,912.74) (4,958.41) (7,061.49) stock-in-trade d Employee benefits expense 4,904.10 4,118.15 4,318.27 9,022.26 8,108.01 17,018.60 e Finance costs 1.49 1.50 5.86 2.99 11.72 23.40 Depreciation and amortisation expense 1,833.54 1,804.73 1,838.96 3,638.27 3,616.59 7,432.51 g Other expenses Power and fuel 3,663.06 3,472.01 2,852.80 7,135.07 5,800.30 11,619.93 Others 4,112.15 4,179.77 3,579.39 8,291.92 6,590.71 14,618.85 Total expenses 22,084.60 19,140.39 17,496.91 41,225.00 33,539.47 75,309.44 3 Profit before exceptional items and tax (1-2) 10,192.21 8,220.96 8,551.75 18,413.16 14,275.71 35,470.72 4 Exceptional items: Statutory impact of new labour codes (refer note 2) 327.54 5 Profit before tax (3-4) 10,192.21 8,220.96 8,551.75 18,413.16 14,275.71 35,143.18 6 Tax expenses: Current tax b Deferred tax Total tax expenses 기 Profit after tax for the period/year (5-6) 2,498.30 122.52 2,036.59 65.00 2,199.60 62.52 4,534.89 3,607.45 8,629.09 187.52 122.07 187.42 2,620.82 2,101.59 2,262.12 4,722.41 3,729.52 8,816.51 7,571.39 6,119.37 6,289.63 13,690.75 10,546.19 26,326.67 8 Other comprehensive income (net of tax) Items that will not be reclassified to profit or loss Re-measurement gain/ (loss) on defined benefit plans b Income tax relating to re-measurement gain/ (loss) on defined benefit plans (103.91) 26.15 71.56 (18.01) 2.02 (0.51) (32.34) 8.14 (30.05) (162.24) 7.56 40.83 c Fair value changes on equity investments through OCI (892.10) d Income tax relating to fair value changes on equity investments through OCI 127.57 1,927.33 (275.61) 2,598.15 (408.99) 1,035.23 (148.04) 2,253.54 (322.26) 6,687.09 (987.87) Other comprehensive income for the period/year (842.29) 1,705.27 2,190.67 862.99 1,908.79 5,577.81 9 Total comprehensive income for the period/year (7+8) 6,729.10 7,824.64 8,480.30 14,553.74 12,454.98 31,904.48 10 Paid-up equity share capital (face value of Rs. 1/- each) 1,046.16 1,046.16 1,046.16 1,046.16 1,046.16 1,046.16 11 Other equity 2,00,929.01 12 Earnings per share Basic and diluted (In Rs.) (not annualised for the quarter) 7.24 5.85 6.01 13.09 10.08 25.17 Refer notes to the unaudited standalone financial results Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website : www.concordbiotech.com
Page 11
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com Notes to the statement of unaudited standalone financial results for the quarter and six months ended September 30, 2026: 1. The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on October 27, 2026. The Statutory Auditors of the company have carried out a limited review of the said results. 2. On November 21, 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour & Employment notified Central Rules and issued FAQs to enable assessment of the financial impact due to changes in regulations. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the company has recognized an incremental liability of 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non- recurring in nature, the impact of the same has been disclosed under exceptional items in the consolidated results for the year ended March 31, 2026. The company continues to monitor further clarifications/FAQ from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed. 3. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment". 4. The above standalone financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI"). 5. Celliimune Biotech Private Limited that was incorporated on January 15, 2025 has been acquired by Concord Biotech Limited as on April 02, 2026. Accordingly, Celliimune Biotech Private Limited is a wholly owned subsidiary from April 02, 2026. 6. The Company has increased the Authorised Share Capital of the Company from 1,100 lacs, divided into 11,00,00,000 (Eleven Crores) Equity Shares of 1/- (Rupees One only) each, to ₹ 2,200 lacs, divided into 22,00,00,000 (Twenty-two crores) Equity Shares of 1/- (Rupees One only) each, by creation of an additional 11,00,00,000 (Eleven Crores) Equity Shares of 1/- (Rupees One only) each, ranking pari passu in all respects with the existing Equity Shares of the Company and consequential amendment to Capital Clause of the Memorandum of Association of the Company, subject to approval of the Shareholders. The company has also declared Bonus shares in the proportion of 1:1 i.e. 1 (One) Bonus equity share of 1/- each for every 1 (One) fully paid-up equity share of 1/- each held by the Shareholders of the Company in the Board meeting held on September 23, 2026. Place: Ahmedabad Date: October 27, 2026 For and on behalf of board of directors of Concord Biotech Limited Sudhir Vaid Chairman & Managing Director DIN: 00055967 Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 12
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com STANDALONE UNAUDITED STATEMENT OF ASSETS & LIABILITIES Particulars Assets I. Non-current assets (a) Property, plant and equipment (b) Capital work-in-progress (c) Intangible assets (d) Right-of use assets (e) Intangible assets under development (f) Financial assets (i) Investments (ii) Other Financial Assets (g) Other non-current assets (h) Income tax assets (net) II. Current assets (a) Inventories (b) Financial assets (i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Other Financial Assets (c) Other Current assets EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity LIABILITIES I. Non-current liabilities (a) Financial liabilities (i) Lease liabilities (b) Provisions (c) Deferred tax liabilities (net) II. Current liabilities (a) Financial liabilities (in Lakhs) As at 30 Sep 2026 (Unaudited) As at 31 March 2026 (Audited) 75,956.79 78,563.34 11,164.94 7,815.92 307.98 24.58 44.60 53.51 139.03 116.51 9,666.09 8,562.52 4,113.87 2,120.45 2,449.32 1,591.53 1,027.94 283.81 Total non-current assets (A) 1,04,870.56 99,132.17 39,298.44 32,568.80 43,810.01 40,206.37 41,865.89 46,060.15 594.38 788.89 13.19 139.30 1,378.22 2,529.66 2.031.86 2,228.44 Total current assets (B) 1,28,991.99 1,24,521.61 TOTAL ASSETS (A) + (B) 2,33,862.55 2,23,653.78 1,046.16 1,046.16 2,07,584.36 2,00,929.01 Total equity (A) 2,08,630.52 2,01,975.17 35.13 45.55 327.74 371.97 4.864.03 4,536.62 Total non-current liabilities (B) 5,226.90 4,954.14 (i) Lease liabilities (ii) Trade payables 19.13 17.43 Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of creditors other than micro enterprises and small enterprises 1,472.98 1,474.95 9,635.36 8,643.23 (iii) Other Financial Liabilities 4,792.17 4,232.53 (b) Provisions 1,243.82 1,123.43 (c) Other current liabilities 2,819.83 1,231.92 (d) Current tax liabilities (net) 21.84 0.98 Total current liabilities (C) 20,005.13 16,724.47 Total Liabilities (D) 25,232.03 21,678.61 TOTAL EQUITY AND LIABILITIES (A) + (D) 2,33,862.55 2,23,653.78 Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 13
CONCORD BIOTECH LIMITED B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 E-mail: complianceofficer@concordbiotech.com Particulars UNAUDITED STANDALONE STATEMENT OF CASH FLOw (A) CASH FLOW FROM OPERATING ACTIVITIES Profit before tax as per Statement of Profit and Loss Adjustment for: For the Six month ended 30 Sep 2026 (Unaudited) ( in Lakhs) For the Six month ended 30 Sep 2025 (Unaudited) 18,413.16 3,638.27 14,275.71 Depreciation and amortization expenses 3,616.59 Provision for sales return 105.26 50.69 Interest Income (124.29) (139.92) Finance Cost 2.99 11.72 (Reversal) /Provision for loss allowance 108.09 97.33 Excess provision no longer required written back (17.89) (179.84) (Profit)/loss on sale/discard of Property, plant & equipment (29.28) (1.30) Net gain on sale of investments (301.85) (989.75) Net gain on financial assets measured at fair value through profit or loss (1,021.44) (238.01) Net unrealised foreign exchange (gain) /loss (277.33) (690.11) Operating Profit before Working Capital Changes 20,495.69 15,813.11 Working Capital Changes: (Increase) in Inventories Decrease in trade receivables Decrease/(Increase) in other financial assets Decrease/(Increase) in other assets (Decrease) in provisions Increase/(Decrease) in trade payables Increase in other financial liabilities Increase in other liabilities Cash generated from operations Direct Taxes paid (Net of Income Tax refund) Net cash generated from operating activities (B) CASH FLOW FROM INVESTING ACTIVITIES (6,729.64) (3,661.01) 4,335.85 13,079.04 432.68 (1,417.93) 207.28 (996.48) (61.45) (113.98) 1,035.71 (2,519.36) 904.42 197.66 1,587.91 673.62 1,712.76 5,241.56 22,208.45 21,054.67 (5,258.16) (6,188.43) 16,950.29 14,866.24 Purchase of Property, plant & equipment and Intangible Assets (including CWIP and capital advance) (5,894.84) (5,344.34) Proceeds from disposal of Property, plant & equipment 36.08 10.65 Acquisition of subsidiary, net of cash (64.80) (2.28) Purchase of Current Investments (42,263.54) (46,133.26) Proceeds from sale of Current Investment 39,979.65 47.780.47 Interest received 124.29 139.92 Proceeds from Bank Deposits (Net) (including margin money deposits) Investment in Current deposits with banks (including margin money deposits) Proceeds from Non current deposits with Bank (including margin money deposits) Net cash used in investing activities (C) CASH FLOW FROM FINANCING ACTIVITIES Repayment of current borrowings 1,431.40 126.11 (1,274.65) (9,231.70) (2,117.44) Dividend Paid (net of TDS) Principal Payment of Lease Liabilities Interest paid on Lease Liabilities Net cash used in financing activities NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A)+(B)+(C) CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR CASH AND CASH EQUIVALENTS AT END OF THE YEAR Cash and cash equivalents comprises of: Cash on hand Balance with Banks Total (38.11) (7,898.40) (11,193.67) (11.71) (98.16) (2.99) (11.72) (7,913.10) (11,341.66) (194.51) 1,407.14 788.89 90.45 594.38 1,497.59 As at 30 Sep 2026 As at 30 Sep 2025 1.98 2.22 592.40 594.38 1,495.37 1,497.59 Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India) Phone: +91-2714-222604, 398200 Fax :+91-2714-222504 Website: www.concordbiotech.com
Page 14
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ----------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------ Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com Encl : As above A. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. - Not Applicable B. Format for Disclosing Outstanding Default on Loans and Debt Securities — Not Applicable, No Default C. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable
Page 15
CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com ----------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------ Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com Annexure – A Audit Committee Sr. No. Name of Member Designation 1. Mr. Arvind Agarwal (Independent Non-Executive Director) Chairman 2. Mr. Jayaram Easwaran (Independent Non-Executive Director) Member 3. Mr. Ravi Kapoor (Non-Independent Director) Member Nomination & Remuneration Committee Sr. No. Name of Member Designation 1. Mr. Mandayam Chakravarthy Sriraman (Independent Non-Executive Director) Chairman 2. Mr. Arvind Agarwal (Independent Non-Executive Director) Member 3. Mrs. Ekta Gupta (Independent Non-Executive Director) Member Risk Management Committee Sr. No. Name of Member Designation 1. Mr. Ankur Vaid (Executive Director) Chairman 2. Mr. Ravi Kapoor (Non-Independent Director) Member 3. Mr. Mandayam Chakravarthy Sriraman (Independent Non-Executive Director) Member Corporate Social Responsibility Committee Sr. No. Name of Member Designation 1. Mr. Ankur Vaid (Executive Director) Chairman 2. Mr. Rajiv Agarwal (Non-Independent Director) Member 3. Mrs. Ekta Gupta (Independent Non-Executive Director) Member